TikoMed has announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with ALS.
Eleven patients participated in the prospective, single-arm, open-label, phase II clinical trial encompassing long-term weekly ILB injections for up to 48 weeks of 2 mg/kg, a dose that was twice that of the dosing of similar patients in a previously published shorter term clinical safety study.
“Taken together, the previous study at the Sahlgrenska Hospital in Gothenburg and the more recent Birmingham trial demonstrate the safety and tolerability of ILB in patients with ALS and further suggest a long-term slowing of disease progression in addition to the already reported rapid improvements in patient biochemistry and residual motor function. The delivery of fast functional benefit alongside long-term disease stabilisation would make ILB a unique treatment option for this devastating disease. These encouraging results indicate the future potential of ILB to be the first disease-modifying drug to treat both familial and sporadic ALS with minimal side-effects,” says TikoMed’s Scientific Advisor, Professor Ann Logan, Honorary Professor of Regenerative Medicine at the University of Warwick.
Photo: iStock
